April 9, 2024 News by Andrea Lobo, PhD Mavenclad now OK’d in UK to also treat active relapsing MS patients The prescribing label for Mavenclad (cladribine) in Great Britain has been extended to include the treatment of adults with active relapsing forms of multiple sclerosis (MS), as defined by clinical or imaging features. This decision made the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) the first to…
January 30, 2024 News by Patricia Inacio, PhD MS treatment Ponvory wins patent protection in US, to run until 2042 The U.S. Patent and Trademark Office (USPTO) has notified Vanda Pharmaceuticals that it will grant a new patent covering the use of Ponvory (ponesimod), an approved oral treatment for relapsing forms of multiple sclerosis (MS), that will span nearly two decades, the company announced. The upcoming patent specifically…
June 13, 2023 News by Marisa Wexler, MS 30 years after MS was first treatable, challenges remain amid triumphs It’s been three decades since the first treatment for multiple sclerosis (MS) was approved. In that time, the field has made substantial advances ā including the approval of over two dozen medications ā but there’s still a long way to go to improve care for progressive forms of…
June 2, 2023 News by Marisa Wexler, MS Briumvi approved in Europe for active, relapsing forms of MS The European Commission has approved Briumvi (ublituximab) for the treatment of adults with relapsing forms of multiple sclerosis (MS) who have active disease, as defined by clinical or imaging features. The approval, which covers all member states in the European Union, as well as Iceland, Norway, and Liechtenstein,…
April 28, 2023 News by Marisa Wexler, MS AAN 2023: MS disability not worse for most on Kesimpta over 5 years More than 80% of patients with relapsing forms of multiple sclerosis (MS) given Kesimpta (ofatumumab) continuously for up to five years in a clinical trial did not have any documented worsening of disability over the duration of the treatment. That’s according to new data from the ongoing…
April 13, 2023 News by Patricia Inacio, PhD FDA puts partial hold on trials of Merck KGaA’s evobrutinib in MS The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on ongoing trials of evobrutinib, Merck KGaA’s experimental BTK inhibitor for relapsing forms of multiple sclerosis (MS). The decision was based on two cases of patients in Phase 3 clinical trials of evobrutinib who were…
March 7, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: GA Depot found to ease MS disability in Phase 3 trial GA Depot, an experimental long-acting version of glatiramer acetate, significantly reduced relapse rates and prevented the development of new lesions among people with relapsing forms of multiple sclerosis, according to new data from a Phase 3 clinical trial. Disability levels also were significantly reduced with the treatment, given…
September 15, 2022 News by Marisa Wexler, MS Study Supports Approved MS Dosage of Ponvory With No Adjustments The approved dosage of the multiple sclerosis (MS) therapy Ponvory (ponesimod) ā 20 mg taken by mouth once daily ā is appropriate for all adults with relapsing forms of MS, a new analysis of data from the OPTIMUM Phase 3 trial found. That analysis showed there was no…
June 23, 2022 News by Marta Figueiredo, PhD Biogen Secures Tecfidera Patent in EU Until 2028; Generics Not Likely Biogen has secured a new patent in Europe covering the use of its oral therapy TecfideraĀ (dimethyl fumarate) for multiple sclerosis (MS) through 2028, the company announced. Granted by the European Patent Office, patent EP2653873 covers the composition and use of dimethyl fumarate at a dose of 480…
April 26, 2022 News by Marisa Wexler, MS Trial of Metformin-Clemastine Combo Enrolls First Patient The first participant has been enrolled in a new clinical trial that is testing whether an antihistamine in combination with a diabetes medication might promote the repair of the myelin sheath in people with multiple sclerosis (MS). The trial’s first participant, Annabelle, was diagnosed with relapsing MS over a…
May 25, 2021 News by Forest Ray PhD Ponvory Approved in EU for Active Relapsing Forms of MS The European Commission has approved PonvoryĀ (ponesimod) to treat adults with relapsing forms of multiple sclerosis (MS) and active disease, as defined by clinical or imaging features. The approval, which follows a recommendation from the Committee for Medicinal Products for Human Use in March, covers clinically isolated…
May 6, 2021 News by Forest Ray PhD Global Phase 3 Trials of Fenebrutinib Enrolling Relapsing and PPMS Patients Two global Phase 3 clinical trials comparing fenebrutinib, anĀ investigational oral BTK inhibitor by Roche, with Aubagio (teriflunomide) are now enrolling adults withĀ relapsing forms of multiple sclerosis (MS), the National MS Society announced in a press release. The twin studies, called FENhance 1 (NCT04586023)…
March 29, 2021 News by Forest Ray PhD Ponvory Recommended for Approval in EU for Relapsing Forms of MS A branch of the European Medicines Agency has recommended that PonvoryĀ (ponesimod) be approved to treat relapsing forms of multiple sclerosisĀ (MS) in adults with active disease. This positive opinion from agency’s Committee for Medicinal Products for Human Use (CHMP) covers clinically isolated syndrome,Ā relapsing-remitting MSĀ (RRMS), andĀ active secondary…
March 10, 2021 News by Forest Ray PhD Emerald Health Preparing for Phase 2 Trial of EHP-101 for Relapsing MS Emerald Health Pharmaceuticals (EHP) is preparing for an international Phase 2 clinical trial testing EHP-101 for the treatment of multiple sclerosis (MS). The study will take place in about 20 locations in the U.S. and Australia, and is expected to include approximately 50 patients with relapsing forms of…